Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Royalty Pharma Plc (NASDAQ: RPRX) shares rose 1.5% in after-hours trading on Monday after the company announced it had acquired the final portion of PTC Therapeutics’ remaining royalty interest in Evrysdi, a leading spinal muscular atrophy (SMA) treatment marketed by Roche. The transaction strengthens Royalty Pharma’s position in one of the most successful rare disease therapies on the market and provides long-term revenue visibility tied to Evrysdi’s global sales growth.
Under the terms of the agreement, Royalty Pharma will pay $240 million upfront to secure the royalty rights, with the potential for up to an additional $60 million in sales-based milestone payments. Upon completion of the deal, Royalty Pharma will own 100% of the tiered royalty structure on Evrysdi, which ranges from 8% to 16% of worldwide net sales. This acquisition further aligns with Royalty Pharma’s strategy of expanding its portfolio of high-quality, cash-generating biopharmaceutical royalties.
Evrysdi is an orally administered SMA treatment that received FDA approval in 2020 and has since been used by more than 21,000 patients worldwide. The drug generated approximately CHF 1.6 billion, or about $1.9 billion, in global sales in 2024, reflecting 18% year-over-year growth at constant exchange rates. Analyst consensus forecasts Evrysdi sales to reach CHF 2.3 billion, or roughly $2.9 billion, by 2030, highlighting the strong long-term growth outlook for the therapy.
The royalty structure provides increasing upside as sales grow. Royalty Pharma will receive 8% on annual sales up to $500 million, 11% on sales between $500 million and $1 billion, 14% on sales between $1 billion and $2 billion, and 16% on sales exceeding $2 billion. The company is expected to begin receiving the higher royalty rates in the first quarter of 2026, based on Evrysdi sales from the fourth quarter of 2025.
Goodwin and Maiwald acted as legal advisors to Royalty Pharma in connection with the transaction, which further solidifies the company’s exposure to a fast-growing rare disease market.
